|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Date | June 2018 | 17.06.2019 | 25.07.2019 | 19.09.2019 | October 2019 | 01.11.2019 | 04.05.2020 | 25.09.2020 | 16.10.2020 | 09.04.2021 | 30.04.2021 | 23.07.2021 | 23.08.2021 | 23.11.2021 | 21.12.2021 |
| Clinical manifestations | first pemphigus symptoms | surgery | lung involvement | lack of pulmonary improvement | consultation with pulmonologist | clinical improvement | | | | | |  |  |  | increased frequency of dyspnoea |
| intravenous immunoglobulins | immunosuppressive dose  2g/kg every four weeks | | | | | | supplementary dose  0.4g/kg according to IgG levels | | increase in dose  1g/kg every three weeks | |  | | supplementary dose  0.4g/kg according to IgG levels | |  |
| Prednisone (per os) |  |  | Increase (1mg/kg/d) | | Decrease (0,5mg/ kg/d) | |  |  |  |  |  |  |  |  |  |
| Rituximab (intravenous infusion) |  |  | 375mg/m2 every 2 weeks |  |  |  |  |  |  |  |  |  |  |  |  |
| tocilizumab (intravenous infusion) |  |  |  | every 2 weeks | | | every 3 weeks | | | | every 4 weeks | | | | every 3 weeks |
|  |  |  |  |  |  | 8 mg/kg | 10mg/kg | | 12mg/kg | |  |  |  | 12mg/kg | 12mg/kg |
| fluticasone & salmeterol (per inhalation) |  |  |  |  |  | 4 at | 50µg |  |  |  |  |  |  |  |  |
| interleukin-6 (pg/mL) |  | 3.4 |  | 6.2 |  | 53.8 |  |  |  |  | 75.3 | 21 |  |  | 30 |

TABLE 1 The dates and doses of immunosuppressive and immunomodulatory medications in presented patient.